Form 4: Black Diamond Therapeutics' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025, according to a recent SEC filing.

Summary

• Sergey Yurasov, the Chief Medical Officer of Black Diamond Therapeutics, Inc., received a grant of 75,000 Restricted Stock Units (RSUs) and options to purchase 200,000 shares of common stock on January 30, 2025.
• The RSUs vest in two equal installments on January 30, 2026, and January 30, 2027, contingent upon continued service.
• The stock options vest 25% on January 30, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, also subject to continued service.
• The exercise price for the stock options is $2.52 per share, and they expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• Vesting schedules tied to continued service incentivize long-term commitment from the executive.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Black Diamond Therapeutics' stock.
• If the executive leaves the company before the vesting dates, they will forfeit the unvested RSUs and stock options.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value creation.
• Comparable companies like Relay Therapeutics and Revolution Medicines also utilize stock options and RSU grants as part of their executive compensation plans.
• The vesting schedules described are fairly typical, with vesting periods ranging from three to four years, contingent on continued service.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates